arrow
P

Peter H. O'Donnell

university of michigan system
H指数:50
被引数:2.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer

SULT2A1基因位点与Abiraterone清除率的关联性:Alliance A031201研究——一项比较Enzalutamide与Enzalutamide联合Abiraterone治疗转移性去势抵抗性前列腺癌的随机III期研究

2025-12-050
OAAI
Results of the ACCOuNT Trial: A Multi-Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients

ACCOuNT试验结果:一项针对非裔美国住院患者的多机构前瞻性药物基因组学实施试验

2025-08-220
OAAI
HER2 and urothelial carcinoma: current understanding and future directions

HER2与尿路上皮癌:当前认知与未来方向

2025-08-150
PRE
Impact of First-of-Its-Kind Patient-Facing Pharmacogenetics Tool on Dosing Decisions and Treatment Outcomes

首款面向患者的药物基因组学工具对剂量决策和治疗结果的影响

2025-06-270
OAAI
Care Team Attributes Predict Likelihood of Utilizing Pharmacogenomic Information During Inpatient Prescribing

护理团队属性预测住院处方期间利用药物基因组学信息的可能性

2025-04-210
OAAI
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial

阿特珠单抗单药治疗转移性尿路上皮癌: imvior210 II期临床试验的最终分析

2024-12-010
PRE
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011
CANCER
IF5.1
2024-10-280
OAAI
NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors (Trial in Progress)
2024-10-010
PRE
Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) plus pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC)

研究EV-103剂量递增/队列A(DE/A):在不可接受顺铂治疗的局部晚期或转移性尿路上皮癌(la/mUC)中,恩沃利单抗偶联物(EV)联合帕博利珠单抗(P)的一线(1L)5年随访研究

2024-09-012
PRE
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy

EV-301既往接受过治疗的晚期尿路上皮癌患者的健康相关生活质量: Enfortumab Vedotin与化疗的3期试验

2024-06-014
OAAI
Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)
2023-10-015
OA
PHASE 2 MULTI-COHORT CLINICAL STUDY EVALUATING DISITAMAB VEDOTIN ALONE AND IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH HER2-EXPRESSING UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA (RC48G001, TRIAL IN PROGRESS)
2022-11-070
OA
Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)
2022-09-0136
OAAI